Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism

Southern Medical Journal

Volumn 89, Issue 6, 1996, Pages 637-640

  Alexander, Tal ^a   Graves, Leland ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; FUROSEMIDE; PAMIDRONIC ACID; PARATHYROID HORMONE; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; FEMALE; FLUID THERAPY; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY TEST; MALE; MEDICAL RECORD; PARATHYROID ADENOMA; PRIMARY HYPERPARATHYROIDISM; STOMACH ULCER;

EID: 15844412404     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-199606000-00020     Document Type: Article

References (18)

1. Diagnosis and management of asymptomatic primary hyperparathyroidism. NIH Consensus Development Conference Statement, October 1990
2. Foldes J, Halperin Y, Kidroni G, et al: Medical treatment of primary hyperparathyroidism: effects on parathormone and vitamin D metabolites. Isr J Med Sci 1987; 23:1148-1151
3. Bilezikian JP: The medical management of hyperparathyroidism. Ann Intern Med 1982; 96:198-202
4. Evans RA: Aminohydroxypropylidene diphosphonate treatment of hypercalcemic crisis due to primary hyperparathyroidism. Aust NZ J Med 1987; 17:58-59
5. Karstrup S, Tranbol I, Holm H, et al: Ultrasound-guided chemical parathyroidectomy in patients with primary hyperparathyroidism: a prospective study. Br J Radiol 1989; 62:1037-1042
6. van Breukelen FJM, Bijvoet OLM, von Oosterom AT: Inhibition of osteolytic bone lesions by 3-amino-1-hydroxypropylidene)-1, 1-diphosphonate (APD). Lancet 1979; 1:803-805
7. Sleebom HP, Bijvoet OLM: Treatment of tumor-induced hypercalcemia. Bone Resorption Metastasis and Diphosphonates. Garattini S (ed). New York, Raven Press, 1985, pp 59-78
8. Morton AR, Cantrill JA, Craig AE, et al: Single dose versus daily intravenous aminohydroxypropylidene diphosphonate (APD) for the hypercalcemia of malignancy. BMJ 1988; 296:811-814
9. Body JJ, Borkowski A, Cleeren A, et al: Treatment of malignancy, associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J Clin Oncol 1986; 4:1177-1183
10. Harwick HIJ, Papadopoulos SE, Blanksma HJ, et al: Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene diphosphonate (APD). BMJ 1987; 295:1301-1305
11. Frijlink WB, Bijvoet OLM, TeVelde J, et al: Treatment of Paget's disease with 3-amino-1-hydroxypropylidene-1, 1-diphosphonate (APD). Lancet 1987; 1:799-803
12. Fitton A, McTavish D: Pamidronate, a review of its pharmacologic properties and therapeutic efficiency in resorptive bone disease. Drugs 1991; 41:289-318
13. Jansson S, Tisell LE, Lindstedt G, et al: Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism. Surgery 1991; 110:480-486
14. Schmidli RS, Wilson I, Espiner EA, et al: Aminopropylidene diphosphonate (APD) in mild primary hyperparathyroidism: effect on clinical status. Clin Endocrinol 1990; 32:293-300
15. Mundy GR: Hypercalcemia of malignancy revisited. J Clin Invest 1988; 82:1-6
16. Adami S, Mian M, Bertoldo F, et al: Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism. Clin Endocrinol 1990; 33:391-397
17. Douglas DL, Kanis JA, Patterson AD, et al: Drug treatment of primary hyperparathyroidism: use of clodronate disoditim. BMJ 1983; 286:587-590
18. Shane B, Baquiran CD, Bilezikian JP: Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. J Intern Med 1981; 95:23-27